Accueil>>Signaling Pathways>> Endocrinology and Hormones>> Androgen Receptor>>JNJ-63576253

JNJ-63576253 (Synonyms: TRC-253)

Catalog No.GC62106

JNJ-63576253 (TRC-253) est un antagoniste complet puissant et actif par voie orale du récepteur aux androgènes (AR), avec des IC50 de 37 et 54 nM pour l'AR mutant F877L et l'AR de type sauvage dans les cellules LNCaP. JNJ-63576253 peut être utilisé pour la recherche sur le cancer de la prostate résistant À la castration (CRPC).

Products are for research use only. Not for human use. We do not sell to patients.

JNJ-63576253 Chemical Structure

Cas No.: 2110428-64-1

Taille Prix Stock Qté
10mM (in 1mL DMSO)
107,00 $US
En stock
5 mg
90,00 $US
En stock
10 mg
153,00 $US
En stock
25 mg
315,00 $US
En stock
50 mg
495,00 $US
En stock
100 mg
855,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

JNJ-63576253 (TRC-253) is a potent and orally active full antagonist of androgen receptor (AR), with IC50s of 37 and 54 nM for F877L mutant AR and wild-type AR in LNCaP cells. JNJ-63576253 can be used for the research of castration-resistant prostate cancer (CRPC)[1].

JNJ-63576253 (0.0003-100 μM; 5 d) inhibits the growth of VCaP cells, with an IC50 of 265 nM[1].JNJ-63576253 is stable in human liver microsomes, with an T1/2 of >180 min[1].

JNJ-63576253 (30 mg/kg; p.o. once daily for 72 days) significantly inhibits the growth of prostate LNCaP SRα F877L tumor in mice[1].JNJ-63576253 (30 mg/kg; p.o. once daily for 10 days) inhibits the five androgen sensitive organs (ASOs) under stimulation by testosterone propionate (TP) in mice[1].JNJ-63576253 (10 mg/kg; p.o.) exhibits moderate oral bioavailability (45%), Cmax (0.66 μM) and AUClast (4.9 μg•h/mL) in mice[1].JNJ-63576253 (2 mg/kg; i.v.) exhibits reasonable half-life (5.99 h), CL (15.0 mL/min/kg) and Vdss (6.11 L/kg) in mice[1].

[1]. Zhang Z, et, al. Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC). J Med Chem. 2021 Jan 28;64(2):909-924.

Avis

Review for JNJ-63576253

Average Rating: 5 ★★★★★ (Based on Reviews and 15 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for JNJ-63576253

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.